Business
Oxford BioMedica Acquires Windrush Court Office
Oxford BioMedica Acquires Windrush Court Office.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 0614U Oxford Biomedica PLC 13 October 2014 \n \n\n \n \n \n \n \n \nOxford BioMedica Acquires Windrush Court Office and Laboratory Facilities\n \n \n \nOxford, UK - 13 October 2014: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Company\") (LSE: OXB), a leading gene and cell therapy company, announces that it has acquired the freehold of the Windrush Court office and laboratory facilities in Transport Way, Oxford, England, for a total cash consideration of £3.2 million from Oxford Real Estate Owner No. 2 Limited. \n \nWindrush Court, a 6,684 sq m facility, is located directly opposite Oxford BioMedica's manufacturing facility and the Company intends to relocate its laboratories and office activities there in stages before the current lease of the Medawar Centre, Oxford expires in March 2016. The purchase of Windrush Court will enable the Company to consolidate its entire activities in Transport Way, improving operational effectiveness, and will also provide additional capacity to accommodate the planned growth in business activities. As a result of the expected savings in rental costs and service charges, Oxford BioMedica expects to recover the purchase cost within 4 years.\n \n \n-Ends-\n \n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\n \nOxford BioMedica plc: \nJohn Dawson, Chief Executive Officer\nTim Watts, Chief Financial Officer\n\n\n \n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nMedia Enquiries:\nMary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton\nConsilium Strategic Communications\n\n\n \n \nTel: +44 (0)20 7309 5700\n\n\n\n\n \n \nNotes for editors\n \nAbout Oxford BioMedica®\n \nOxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently ...